On Tuesday, Biogen Inc (NASDAQ: BIIB) opened higher 3.33% from the last session, before settling in for the closing price of $130.13. Price fluctuations for BIIB have ranged from $110.04 to $238.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -18.66% annually for the last half of the decade. Company’s average yearly earnings per share was noted -10.07% at the time writing. With a float of $146.25 million, this company’s outstanding shares have now reached $146.50 million.
In an organization with 7605 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 75.58%, operating margin of 23.17%, and the pretax margin is 17.85%.
Biogen Inc (BIIB) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Biogen Inc is 0.19%, while institutional ownership is 89.87%. The most recent insider transaction that took place on Jul 08 ’25, was worth 300,105. Before that another transaction happened on May 19 ’25, when Company’s Head of Development sold 3,806 for $126.25, making the entire transaction worth $480,508. This insider now owns 5,427 shares in total.
Biogen Inc (BIIB) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -10.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.80% during the next five years compared to -18.66% drop over the previous five years of trading.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
Check out the current performance indicators for Biogen Inc (BIIB). In the past quarter, the stock posted a quick ratio of 1.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.10. Likewise, its price to free cash flow for the trailing twelve months is 8.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.13, a number that is poised to hit 4.06 in the next quarter and is forecasted to reach 15.41 in one year’s time.
Technical Analysis of Biogen Inc (BIIB)
Let’s dig in a bit further. During the last 5-days, its volume was 1.29 million. That was inferior than the volume of 1.59 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.18%.
During the past 100 days, Biogen Inc’s (BIIB) raw stochastic average was set at 51.90%, which indicates a significant decrease from 90.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.81 in the past 14 days, which was lower than the 4.07 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $126.87, while its 200-day Moving Average is $147.59. However, in the short run, Biogen Inc’s stock first resistance to watch stands at $136.59. Second resistance stands at $138.71. The third major resistance level sits at $141.85. If the price goes on to break the first support level at $131.33, it is likely to go to the next support level at $128.19. Assuming the price breaks the second support level, the third support level stands at $126.07.
Biogen Inc (NASDAQ: BIIB) Key Stats
There are currently 146,528K shares outstanding in the company with a market cap of 19.70 billion. Presently, the company’s annual sales total 9,676 M according to its annual income of 1,632 M. Last quarter, the company’s sales amounted to 2,431 M and its income totaled 240,500 K.
